Table 4 Baseline characteristics related to early neurological deterioration after acute cerebral infarction.
END | non-END | P value | |
---|---|---|---|
Age (years) | 68.34 ± 5.86 | 67.53 ± 7.72 | 0.201 |
Male | 122 (71.35%) | 272 (60.44%) | 0.617 |
Body mass index (kg/m2) | 25.31 ± 1.58 | 24.97 ± 1.83 | 0.031 |
Systolic blood pressure (mmHg) | 138.81 ± 21.10 | 141.27 ± 20.54 | 0.284 |
Diastolic blood pressure (mmHg) | 79.87 ± 13.64 | 80.11 ± 12.06 | 0.847 |
Smoker AlcoholAdmission time (hours) | 101 (59.06%) | 234 (52.00%) | 0.115 |
Blood-collection time (hours) | 101 (59.06%) | 239 (53.11%) | 0.183 |
Comorbidity | 6.40 (5.20–7.60) | 6.10 (4.90–7.30) | 0.377 |
Diabetes mellitus | 7.00 (6.20–8.30) | 7.30 (6.00–8.50) | 0.416 |
Hypertension | ` | ||
Coronary heart disease | 77 (45.03%) | 154 (34.22%) | 0.013 |
Dyslipidemia | 90 (52.63%) | 267 (59.33%) | 0.131 |
Treatment | 63 (36.84%) | 139 (30.89%) | 0.157 |
Thrombolysis | 98 (57.31%) | 219 (48.67%) | 0.054 |
Antiplatelet | |||
Statins | 60 (35.09%)106 (61.99%) | 133 (29.56%) | 0.183 |
Anticoagulant | 32 (18.71%) | 297 (66.00%) | 0.446 |
GLP-1 agonists | 10 (5.85%) | 93 (20.67%) | 0.737 |
SGLT2 inhibitorsNIHSS score | 13 (8.07%) | 32 (7.11%) | 0.772 |
Stroke etiology | 34 (21.12%) | 24 (5.22%) | 0.187 |
Small-vessel occlusive | 14.00 (12.00–17.00) | 81 (17.61%) | 0.324 |
Large-vessel occlusive | 12.00 (13.00–16.00) | 0.019 | |
Cardioembolic | 42 (24.56%) | 0.496 | |
Others | 55 (32.16%) | 122 (27.11%) | |
Infarction volume (cm3) | 39 (22.81%) | 143 (31.78%) | |
TOAST subtype | 35 (20.47%) | 86 (19.11%) | |
Large artery atherosclerosis | 18.90 (6.40–30.18) | 99 (22.00%) | |
Small artery occlusions | 13.50 (2.90–25.70) | 0.019 | |
Cardioembolism | 52 (30.41%) | 0.091 | |
Infarct location | 93(54.39%) | 179 (39.78%) | |
Anterior circulation infarct | 26 (15.20%) | 216 (48.00%) | |
Posterior circulation infarct | 55 (12.22%) | ||
Lacunar infarct | 100 (58.48%) | 0.060 | |
Laboratory data | 44 (25.73%) | 216 (48.62%) | |
Serum triglycerides levels (mg/dL) | 27 (15.79%) | 138 (30.67%) | |
Serum total cholesterol levels (mg/dL) | 96 (21.33%) | ||
Serum HDL-c levels (mg/dL) | 100.05 ± 31.92 | ||
Serum LDL-c levels (mg/dL) | 215.67 ± 42.31 | 101.51 ± 29.60 | 0.585 |
Serum glucose levels (mg/dL) | 50.03 ± 16.53 | 211.76 ± 52.99 | 0.372 |
Serum PDMPs levels (ng/L) | 138.06 ± 35.83 | 49.24 ± 16.04 | 0.576 |
Platelet count (× 109/L) | 122.27 ± 39.82 | 135.95 ± 45.12 | 0.573 |
APTT (s) | 30.31 ± 7.72 | 115.50 ± 44.06 | 0.003 |
TT (s) | 252.84 ± 97.63 | 25.00 ± 8.15 | 0.003 |
Serum fibrinogen levels (g/L) | 28.11 ± 4.43 | 239.11 ± 90.89 | 0.092 |
12.36 ± 4.03 | 27.52 ± 4.21 | 0.112 | |
4.48 ± 1.42 | 11.98 ± 2.90 | 0.188 | |
4.19 ± 1.60 | 0.030 |